Gradient Capital Advisors LLC Invests $344,000 in Bristol-Myers Squibb (NYSE:BMY)

Gradient Capital Advisors LLC acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 4,833 shares of the biopharmaceutical company’s stock, valued at approximately $344,000.

Other large investors have also modified their holdings of the company. Xponance Inc. boosted its stake in shares of Bristol-Myers Squibb by 28.0% during the 3rd quarter. Xponance Inc. now owns 219,534 shares of the biopharmaceutical company’s stock worth $15,607,000 after acquiring an additional 47,993 shares in the last quarter. Grimes & Company Inc. lifted its holdings in shares of Bristol-Myers Squibb by 1.6% in the third quarter. Grimes & Company Inc. now owns 295,464 shares of the biopharmaceutical company’s stock valued at $21,005,000 after purchasing an additional 4,778 shares in the last quarter. Brown Advisory Inc. grew its holdings in shares of Bristol-Myers Squibb by 3.9% during the second quarter. Brown Advisory Inc. now owns 256,514 shares of the biopharmaceutical company’s stock valued at $18,237,000 after buying an additional 9,635 shares in the last quarter. Cliftonlarsonallen Wealth Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 2.2% during the third quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 12,366 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 261 shares in the last quarter. Finally, Advocate Group LLC grew its holdings in shares of Bristol-Myers Squibb by 9.0% during the third quarter. Advocate Group LLC now owns 97,286 shares of the biopharmaceutical company’s stock valued at $6,916,000 after buying an additional 7,998 shares in the last quarter. 75.51% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded up $0.09 during trading hours on Wednesday, reaching $72.43. 781,493 shares of the company were exchanged, compared to its average volume of 8,047,362. The firm has a market cap of $154.00 billion, a price-to-earnings ratio of 23.56, a PEG ratio of 1.63 and a beta of 0.44. The company has a current ratio of 1.42, a quick ratio of 1.31 and a debt-to-equity ratio of 1.13. The stock has a 50-day moving average of $75.32 and a 200 day moving average of $73.70. Bristol-Myers Squibb has a 12 month low of $61.86 and a 12 month high of $81.43.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last announced its earnings results on Tuesday, October 25th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.16. The firm had revenue of $11.22 billion during the quarter, compared to analysts’ expectations of $11.18 billion. Bristol-Myers Squibb had a return on equity of 50.30% and a net margin of 14.29%. The company’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.00 earnings per share. As a group, research analysts anticipate that Bristol-Myers Squibb will post 7.61 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Shareholders of record on Friday, January 6th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, January 5th. This represents a $2.28 dividend on an annualized basis and a yield of 3.15%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.54. Bristol-Myers Squibb’s dividend payout ratio is presently 74.27%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group reiterated a “buy” rating and set a $85.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, September 27th. Cantor Fitzgerald assumed coverage on Bristol-Myers Squibb in a report on Tuesday, January 17th. They set an “overweight” rating and a $95.00 price target on the stock. Barclays lowered their price target on Bristol-Myers Squibb from $69.00 to $66.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 12th. Atlantic Securities lifted their price target on Bristol-Myers Squibb from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, November 10th. Finally, Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $70.00 to $78.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 3rd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $80.60.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Rupert Vessey sold 45,910 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $78.88, for a total transaction of $3,621,380.80. Following the completion of the transaction, the executive vice president now directly owns 57,079 shares in the company, valued at $4,502,391.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Rupert Vessey sold 45,910 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $78.88, for a total transaction of $3,621,380.80. Following the completion of the transaction, the executive vice president now directly owns 57,079 shares in the company, valued at $4,502,391.52. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Ann Powell sold 16,250 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $80.45, for a total value of $1,307,312.50. Following the transaction, the executive vice president now owns 34,226 shares of the company’s stock, valued at $2,753,481.70. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.